MamieMcFaddin Ward Cancer Center

Beaumont, Texas 77702-1449

0 studies enrolling now · 16 studies all time

What they study most

Androgen-independent Prostate Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Gastric Cancer Adenocarcinoma Metastatic, Hormone Refractory Prostate Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Rectal Cancer, Small Cell Lung Cancer

Studies at this site

• PhII ICb With/Without Erbitux in MBC Pts — Running, not enrolling
• TAC Versus TC for Adjuvant Breast Cancer — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy — Completed
• Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer — Completed
• Phase II Sunitinib Prog Met AIPC — Completed
• Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) — Completed
• Docetaxel+Oxali+/-Cetux Met Gastric/GEJ — Completed
• Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer — Completed
• Adj TC + Herceptin Early Stage Breast Cancer — Completed
• Pre-op Rectal ChemoRad +/- Cetuximab — Completed
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — Completed
• Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) — Completed
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) — Stopped early